PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma

The American Journal of Surgical Pathology
Anjelica HodgsonMichelle R Downes

Abstract

Programmed death ligand-1 (PD-L1) immunohistochemistry is used to guide treatment decisions regarding the use of checkpoint immunotherapy in the management of urothelial carcinoma of the bladder and hypopharyngeal (HP) squamous cell carcinoma. With increasing PD-L1 testing options, a need has arisen to assess the analytical comparability of diagnostic assays in order to develop a more sustainable testing strategy. Using tissue microarrays, PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was manually scored in 197 cases and 27 cases of bladder and HP cancer, respectively. Three commercial kits (Ventana SP263, Ventana SP142, Dako 22C3) and 1 platform-independent test (Cell Signalling Technologies E1L3N) were utilized. Across the 3 commercially available clones, 14% and 74% of urothelial carcinomas were positive and negative, respectively, whereas 7% and 78% of HP carcinomas were positive and negative, respectively. Twelve percent of bladder and 15% HP cases showed discrepant PD-L1 classification results. Regardless of the scoring algorithm used, E1L3N provided comparable PD-L1 staining results. Fleiss' kappa and intraclass correlation coefficient (ICC) analyses demonstrated substantial agreement among all antibody cl...Continue Reading

References

Feb 4, 2009·Head & Neck·Jay S CooperCorey J Langer
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Sep 27, 2014·Nature Reviews. Immunology·Daniel E SpeiserDietmar Zehn
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A PostowJedd D Wolchok
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Mar 24, 2015·Trends in Immunology·Kristen E Pauken, E John Wherry
Jan 13, 2016·Archives of Pathology & Laboratory Medicine·Keith M Kerr, Fred R Hirsch
Aug 19, 2016·Current Oncology·D DayL L Siu
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm
Sep 4, 2016·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Brandon S SheffieldDiana N Ionescu
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Nov 12, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jamaal A RehmanDavid L Rimm
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Jan 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marianne J RatcliffeJill Walker
Feb 20, 2017·Cancer Treatment Reviews·Joaquin BellmuntNicholas J Vogelzang
Aug 30, 2017·Histopathology·Andreas H ScheelJosef Rüschoff
Oct 11, 2017·Expert Review of Clinical Pharmacology·Michael Crist, Arjun Balar
Dec 23, 2017·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Maria TretiakovaAllen Gown

❮ Previous
Next ❯

Citations

Feb 6, 2020·International Journal of Molecular Sciences·João LoboRui Henrique
Feb 23, 2020·Expert Opinion on Biological Therapy·Alessia CimadamoreRodolfo Montironi
Feb 6, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Yujun ParkHye Seung Lee
Jul 14, 2018·Histopathology·Joep J de JongGeert J L H van Leenders
Aug 8, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Emma J de RuiterStefan M Willems
Feb 9, 2020·Virchows Archiv : an International Journal of Pathology·Francesco PiercontiCarlo Patriarca
Aug 18, 2018·Nature Reviews. Urology·Min Yuen Teo, Jonathan E Rosenberg
Oct 3, 2020·Journal for Immunotherapy of Cancer·Claire F FriedmanDmitriy Zamarin
Nov 4, 2020·World Journal of Urology·Mathieu RouanneYves Allory
Nov 12, 2020·Virchows Archiv : an International Journal of Pathology·Bin XuElzbieta Slodkowska
Jan 7, 2021·Cancers·Antonio Lopez-BeltranRodolfo Montironi
Mar 28, 2020·Current Drug Targets·Kerstin JunkerRodolfo Montironi
Jan 24, 2020·Current Drug Targets·Francesca GiunchiMichelangelo Fiorentino
Mar 20, 2021·Cancer Immunology, Immunotherapy : CII·Chien-Hsu ChenPo-Hui Chiang
Apr 29, 2021·Virchows Archiv : an International Journal of Pathology·Joep J de JongGeert J L H van Leenders
May 7, 2021·Der Pathologe·Hans-Ulrich Schildhaus, Wilko Weichert
Apr 7, 2021·Journal of Pathology and Translational Medicine·Kyu Sang Lee, Gheeyoung Choe
Jun 23, 2021·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Ilaria GirolamiAlbino Eccher
May 11, 2020·Current Drug Targets·Thomas GevaertMarkus Eckstein

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
surgical resections
biopsy
biopsies

Software Mentioned

SPSS

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.